EXOMIND® Brain Stimulation Therapy in Calgary, Alberta

EXOMIND is a non-invasive, drug-free brain stimulation therapy that uses repetitive transcranial magnetic stimulation (rTMS). It is intended for specific clinical uses, including major depressive disorder (MDD), according to the device’s Canadian licence. A clinical screening is needed to determine whether it may be appropriate for you.

EXOMIND uses its ExoTMS™ technology to stimulate targeted areas of the brain involved in emotional regulation and other functions. Treatment is intended to influence brain activity through repeated stimulation. Your healthcare provider can explain the treatment approach and whether it fits your clinical needs.

According to the product fact sheet’s description of the Health Canada licence, EXOMIND is intended for repetitive transcranial magnetic stimulation and specified uses that include major depressive disorder in adults who have not achieved satisfactory improvement with prior antidepressant medication at an adequate dose and duration; reduction of symptoms of comorbid anxiety in patients with MDD; adjunctive treatment of adults with obsessive-compulsive disorder (OCD); and treatment of binge eating disorder (BED). A clinician should confirm whether your circumstances meet the relevant criteria.

EXOMIND is a non-medication-based treatment procedure. It may be considered as part of a treatment plan, but it does not mean that you should stop or change prescribed medication. Discuss medication and other treatment decisions with your prescribing healthcare professional.

EXOMIND may be considered for people whose symptoms and clinical history fit its authorized indications. Suitability depends on your health history, current symptoms, treatment goals, and any contraindications or precautions. A clinical screening is required before treatment.

A course of rTMS generally involves multiple treatments. The number of sessions and treatment schedule depend on the individual and should be discussed with your treating healthcare provider. Follow-up care may also be recommended.

During treatment, you will be positioned comfortably while the applicator is placed on your head. You may feel a tapping or tingling sensation in the treated area. Some people experience temporary discomfort or a headache. Your provider can explain what to expect and help address discomfort during treatment.

The product fact sheet states that many patients find treatment comfortable and that sessions last under 30 minutes. Sensations can vary between individuals. Ask your provider about the expected appointment length for your treatment plan.

The product fact sheet describes EXOMIND as a walk-in, walk-out procedure and states that patients can generally resume normal activities immediately after a session. Your healthcare provider will advise you if any individual precautions apply.

The product fact sheet states that rTMS is generally well tolerated, but possible risks can include headache, scalp pain, seizure, and hypomania. Discuss the potential benefits, risks, contraindications, and precautions with your healthcare provider before starting treatment. Report any concerning symptoms to your provider.

The duration of benefits varies from person to person. The product fact sheet notes that clinical reports have suggested benefits may last up to 12 months for some people, although this is not guaranteed. Like regular exercise, the positive effects you experience may diminish over time, and ongoing care may be helpful in maintaining your progress.

After completing your initial course of treatment and experiencing positive results, we recommend speaking with your clinician about whether maintenance or booster sessions may be appropriate for you. Booster sessions are typically considered around every three months, depending on your individual needs and response to treatment. Follow-up monitoring and additional treatment, including medication where clinically indicated, may also be recommended by your healthcare provider.

The product fact sheet describes the Canadian licence as including reduction of symptoms of comorbid anxiety in patients who have major depressive disorder. This should not be interpreted as a claim that EXOMIND is indicated for every anxiety disorder on its own. A healthcare provider can discuss whether your symptoms fit the authorized use.

The product fact sheet describes the Canadian licence as including adjunctive treatment for adults with OCD and treatment of binge eating disorder (BED). A clinician should assess whether treatment is appropriate for your circumstances and explain how it may fit with other recommended care.

The product fact sheet describes a Health Canada licence for specified rTMS uses and US FDA clearance for major depressive disorder in adult patients who have not achieved satisfactory improvement from prior antidepressant medication in the current episode. Regulatory wording and authorized indications differ by country. Confirm the current licence and indication for the device offered at the clinic before treatment.

Other treatment options may include medication, psychotherapy, and—in some circumstances—electroconvulsive therapy or other clinically appropriate treatments. The best options depend on your symptoms, preferences, history, and clinical needs. Discuss alternatives with your healthcare provider.